Drug intelligence / Profile preview

ATYR0750

Development stage: Preclinical
Lead developer: aTyr Pharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

ATYR0750 is a research-stage recombinant fusion protein developed by aTyr Pharma, derived from a domain of alanyl-tRNA synthetase (AARS). It acts as a selective ligand for fibroblast growth factor receptor 4 (FGFR4), a receptor involved in cell proliferation, differentiation, and tissue repair. By activating FGFR4, ATYR0750 is designed to modulate inflammation and fibrosis, particularly in the liver. Preclinical research has demonstrated that ATYR0750 selectively binds to FGFR4 and induces downstream signaling pathways with functional similarities to FGF2, suggesting potential therapeutic utility in treating chronic liver disorders.

Other names: AARS-derived fusion protein

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on ATYR0750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATYR0750.

Explore the full profile